Retatrutide
Chemical compoundComposé chimique
Retatrutide is an experimental drug for obesity developed by the American pharmaceutical company Eli Lilly and Company. It is a triple hormone receptor agonist on the GLP-1, GIP, and glucagon receptors.
ATK 4139DEF 3358
